Takeda Oncology is committed to bringing innovative solutions to evolve the treatment landscape in  Metastatic Colorectal Cancer (mCRC)

Learn about Takeda Oncology's dedication to developing innovative solutions for metastatic colorectal cancer (mCRC) treatment. 

Takeda Oncology's Commitment to Advancing Metastatic Colorectal Cancer | Takeda Oncology 

Newsroom

# Dedicated to Finding Innovative Solutions in Metastatic Colorectal Cancer



**Metastatic colorectal cancer (mCRC) is the second most common cause of cancer-related mortalities worldwide. With the global incidence of mCRC on the rise, treatment advancements in efficacy and tolerability are vital.** Takeda Oncology is committed to bringing innovative solutions to evolve the treatment landscape in mCRC.


## Welcome



Divider Section

## Resources



mCRC Fact Sheet

Download Fact Sheet

Metastatic Colorectal Cancer Fact Sheet

Visit our newsroom to read the latest oncology news releases

News Releases

Read News

The Power of Partnership: Transforming Cancer Care

Article

Teresa Bitetti

The Urgent Need for Innovation in Colorectal Cancer Treatment

Jennifer Burke Elliott

Oncology Pipeline

Explore More

Cancel

You are now leaving Takedaoncology.com and entering a website that is not owned or controlled by Takeda. 

Takeda Oncology makes no representation as to the accuracy of the information contained on websites we do not own or control. Takeda Oncology does not recommend or endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.
